Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

16.07.2019 | short review | Ausgabe 3/2019

memo - Magazine of European Medical Oncology 3/2019

Post San Antonio: immunotherapy, chemotherapy and new combinations

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2019
Autoren:
MD Karl Mayrhofer, MD, MBA Kathrin Strasser-Weippl
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

This article gives a summary of several studies presented at the San Antonio Breast Cancer Symposium in 2018. In specific, the biomarker analysis of the ‘IMpassion130’ trial, the effects of CDK4/6 inhibitors on T-cells and tumor immunogenicity, adjuvant chemotherapy in older patients, the prognostic relevance of achieving a pathologic complete response after neoadjuvant therapy, the quality of life analysis of the ‘TAILORx’ trial, the prognostic impact of detecting bone marrow tumor cells at the time of primary resection and b-cell lymphoma 2 as a new possible therapeutic target in luminal breast cancer, are discussed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2019

memo - Magazine of European Medical Oncology 3/2019 Zur Ausgabe